I-Mab Starts China Trial of GM-CSF Inhibitor for RA

Shanghai's I-Mab has dosed the first patient in a Phase Ib trial of plonmarlimab (TJM2) in patients with rheumatoid arthritis (RA) in China. Plonmarlimab is a humanized immunoglobulin G1 (IgG1) antibody. It targets the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), which plays a critical role in autoimmune and inflammatory disease. Neutralizing GM-CSF diminishes inflammatory responses. In the US, a Phase II trial is underway to test TJM2 in patients with cytokine release syndrome caused by COVID-19. More details.... Stock Symbol: (NSDQ: IMAB) Share this with colleagues: // //